BMS 986168

Drug Profile

BMS 986168

Alternative Names: Anti-eTau; BMS-986168; IPN-007

Latest Information Update: 19 Apr 2016

Price : $50

At a glance

  • Originator iPierian
  • Developer Bristol-Myers Squibb; iPierian
  • Class Monoclonal antibodies; Neuropsychotherapeutics
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Progressive supranuclear palsy
  • Discontinued Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 03 Mar 2017 Bristol-Myers Squibb plans a phase II trial for Progressive supranuclear palsy (NCT03068468)
  • 01 Apr 2016 Bristol-Myers Squibb completes a phase I trial in Progressive supranuclear palsy in USA (IV) (NCT02294851)
  • 01 Feb 2016 Bristol Myers Squibb initiates an extension phase I study for Progressive supranuclear palsy in USA (NCT02658916)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top